HOOK Insider Trading
Insider Ownership Percentage: 3.30%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Hookipa Pharma Insider Trading History Chart
This chart shows the insider buying and selling history at Hookipa Pharma by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Hookipa Pharma Share Price & Price History
Current Price: $1.95
Price Change: ▲ Price Increase of +0.01 (0.52%)
As of 01/17/2025 05:00 PM ET
Hookipa Pharma Insider Trading History
Hookipa Pharma Institutional Trading History
Data available starting January 2016
HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.
Read More on Hookipa Pharma
Volume
78,179 shs
Average Volume
95,853 shs
Market Capitalization
$23.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.71
Who are the company insiders with the largest holdings of Hookipa Pharma?